Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Συνδρομές Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Ενδείξεις και αγωγές Βρείτε θεραπευτικές ενδείξεις και αγωγές για νόσους, συμπτώματα και ιατρικές πράξεις
Γνωρίζατε ότι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα

MONOFER Solution for injection / infusion (2019)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Monofer 100 mg/ml solution for injection/infusion.

Qualitative and quantitative composition

One millilitre of solution contains 100 mg iron as iron(III) isomaltoside 1000. 1 ml vial/ampoule contains 100 mg iron as iron(III) isomaltoside 1000. 2 ml vial/ampoule contains 200 mg iron as iron(III) ...

Pharmaceutical form

Solution for injection/infusion. Dark brown, non-transparent solution.

Therapeutic indications

Monofer is indicated for the treatment of iron deficiency in the following conditions: When oral iron preparations are ineffective or cannot be used. Where there is a clinical need to deliver iron rapidly. ...

Posology and method of administration

Calculation of the cumulative iron need Iron replacement in patients with iron deficiency The dose of Monofer is expressed in mg of elemental iron. The iron need and the administration schedule for Monofer ...

Contraindications

Hypersensitivity to the active substance, to Monofer or any of its excipients listed in section 6.1. Known serious hypersensitivity to other parenteral iron products. Non-iron deficiency anaemia (e.g. ...

Special warnings and precautions for use

Parenterally administered iron preparations can cause hypersensitivity reactions including serious and potentially fatal anaphylactic/anaphylactoid reactions. Hypersensitivity reactions have also been ...

Interaction with other medicinal products and other forms of interaction

As with all parenteral iron preparations the absorption of oral iron is reduced when administered concomitantly. Oral iron therapy should not be started earlier than 5 days after the last injection of ...

Fertility, pregnancy and lactation

Pregnancy There are no adequate and well-controlled trials of Monofer in pregnant women. A careful risk/benefit evaluation is therefore required before use during pregnancy and Monofer should not be used ...

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

Undesirable effects

The table presents the adverse drug reactions (ADRs) reported during Monofer treatment in clinical trials and in-market experience. Acute severe hypersensitivity reactions may occur with parenteral iron ...

Overdose

The iron(III) isomaltoside 1000 in Monofer has a low toxicity. The preparation is well tolerated and has a minimal risk of accidental overdosing. Overdose may lead to accumulation of iron in storage sites ...

Pharmacodynamic properties

Pharmacotherapeutic group: Iron parenteral preparation ATC code: B03AC Monofer solution for injection is a colloid with strongly bound iron in spheroidal iron-carbohydrate particles. The Monofer formulation ...

Pharmacokinetic properties

The Monofer formulation contains iron in a strongly bound complex that enables a controlled and slow release of bioavailable iron to iron-binding proteins with little risk of free iron toxicity. After ...

Preclinical safety data

Iron complexes have been reported to be teratogenic and embryocidal in non-anaemic pregnant animals at high single doses above 125 mg iron/kg body weight. The highest recommended dose in clinical use is ...

List of excipients

Water for injections Sodium hydroxide (for pH adjustment) Hydrochloric acid (for pH adjustment)

Incompatibilities

This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.

Shelf life

Shelf life Shelf life of ampoules as packaged for sale: 3 years. Shelf life of vials as packaged for sale: 3 years. Shelf life after first opening of the container (undiluted): From a microbiological point ...

Special precautions for storage

This medicinal product does not require any special storage conditions. For storage conditions of the reconstituted and diluted solution, see section 6.3.

Nature and contents of container

Type 1 glass ampoule. Pack sizes: 5 1 ml, 10 1 ml, 5 2 ml, 10 2 ml, 2 5 ml, 5 5 ml, 2 10 ml, 5 10 ml Type 1 glass vial with chlorobutyle rubber stopper and aluminium cap. Pack sizes: 1 1 ml, 5 ...

Special precautions for disposal and other handling

Inspect vials/ampoules visually for sediment and damage before use. Use only those containing sediment-free, homogeneous solution. Monofer is for single use only and any unused solution should be disposed ...

Marketing authorization holder

Pharmacosmos A/S, Roervangsvej 30, DK-4300, Holbaek, Denmark

Marketing authorization number(s)

PL 18380/001

Date of first authorization / renewal of the authorization

Date of first authorisation: 2009-11-26 Date of latest renewal: 2014-11-26

Date of revision of the text

08.07.2019

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση:

Μπορείτε να υποστηρίξετε τον Γαληνό στην αποστολή του να παρέχει δωρεάν έγκυρη πληροφόρηση για κάθε φάρμακο απενεργοποιώντας το Ad Blocker για αυτόν τον ιστότοπο.